Headsafe

Headsafe operates at the intersection of medical devices, digital health, diagnostics, and sports medicine. Its core differentiation is a portable EEG and visual evoked potential system intended to provide objective brain-function data for concussion and mild traumatic brain injury assessment. The company positions Nurochek as the world’s first FDA-cleared portable brain scanner, with results available in approximately two minutes and no baseline test requirement. That combination gives Headsafe a distinct point-of-care proposition for emergency rooms, urgent care, ambulances, clinics, sports medicine settings, and sidelines. Public information does not identify a sufficiently comparable named competitor set, so direct market-share or product-by-product comparisons would be premature. The company’s competitive advantages appear to come from regulatory clearance, seven international patents, portability, and an operating model that combines hardware, clinical deployment, training, and support. Its limitations are also visible: the business remains small, with an indicated workforce of 1-10 employees, and its disclosed funding totals only $130,000 despite its international commercialization ambitions.

Headsafe shows a transition from an Australian concussion education and research organization into a regulated medical-device commercialization business. The company was founded in 2017 and raised a $130,000 Angel round from Sydney Angels on Dec 21, 2017. A later Venture Round on Sep 29, 2024 included Pacific Channel, although the amount is undisclosed. The clearest inflection point came in January 2026, when Headsafe launched Nurochek in the U.S. healthcare market and appointed Craig Corrance as CEO to lead commercialization. The company then added Spartan Medical as a U.S. distribution partner on Mar 31, 2026 and 4U Solutions as a regional commercial partner on Jun 9, 2026. MDSAP registration on May 19, 2026 supports broader international market access, while the U.S. parent-company announcement on Sep 2, 2026 suggests an organizational platform for global expansion. Leadership also expanded through the appointment of Philip Gower as Chief Strategy and Commercial Officer in January 2026. Growth is therefore being driven more by regulatory progress, distribution infrastructure, and executive capacity than by disclosed capital deployment or headcount expansion.